Alexander Trofimov

Dr. Alexander Trofimov

Department of Biology, Nazarbayev University, Nur-Sultan, Astana, Kazakhstan
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2016 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
YCYvonne Couch
Yvonne Couch
Alexander TrofimovAlexander Trofimov
Alexander Trofimov
NMNatalyia Markova
Natalyia Markova
VNVladimir Nikolenko
Vladimir Nikolenko
HSHarry W. Steinbusch
Harry W. Steinbusch
TSTatyana Strekalova
Tatyana Strekalova
Aggression, hyperactivity, impulsivity, helplessness and anhedonia are all signs of depressive-like disorders in humans and are often reported to be present in animal models of depression induced by stress or by inflammatory challenges. However, chronic mild stress (CMS) and clinically silent inflammation, during the recovery period after an infection, for example, are often coincident, but comparison of the behavioural and molecular changes that underpin CMS vs a mild inflammatory challenge and impact of the combined challenge is largely unexplored. Here, we examined whether stress-induced behavioural and molecular responses are analogous to lipopolysaccharide (LPS)-induced behavioural and molecular effects and whether their combination is adaptive or maladaptive. Changes in measures of hedonic sensitivity, helplessness, aggression, impulsivity and CNS and systemic cytokine and 5-HT-system-related gene expression were investigated in C57BL/6J male mice exposed to chronic stress alone, low-dose LPS alone or a combination of LPS and stress. When combined with a low dose of LPS, chronic stress resulted in an enhanced depressive-like phenotype but significantly reduced manifestations of aggression and hyperactivity. At the molecular level, LPS was a strong inducer of TNFα, IL-1β and region-specific 5-HT2A mRNA expression in the brain. There was also increased serum corticosterone as well as increased TNFα expression in the liver. Stress did not induce comparable levels of cytokine expression to an LPS challenge, but the combination of stress with LPS reduced the stress-induced changes in 5-HT genes and the LPS-induced elevated IL-1β levels. It is evident that when administered independently, both stress and LPS challenges induced distinct molecular and behavioural changes. However, at a time when LPS alone does not induce any overt behavioural changes per se, the combination with stress exacerbates depressive and inhibits aggressive behaviours.

15 July 2022 in Frontiers in Nutrition
Verified
Journal Article
Open access
Ksenia ShcherbakovaKsenia Shcherbakova
Ksenia Shcherbakova
ASAlexander Schwarz
Alexander Schwarz
SASergey Apryatin
Sergey Apryatin
MKMarina Karpenko
Marina Karpenko
Alexander TrofimovAlexander Trofimov
Alexander Trofimov
It is now widely accepted that ketosis (a physiological state characterized by elevated plasma ketone body levels) possesses a wide range of neuroprotective effects. There is a growing interest in the use of ketogenic supplements, including medium-chain triglycerides (MCT), to achieve intermittent ketosis without adhering to a strict ketogenic diet. MCT supplementation is an inexpensive and simple ketogenic intervention, proven to benefit both individuals with normal cognition and those suffering from mild cognitive impairment, Alzheimer's disease, and other cognitive disorders. The commonly accepted paradigm underlying MCT supplementation trials is that the benefits stem from ketogenesis and that MCT supplementation is safe. However, medium-chain fatty acids (MCFAs) may also exert effects in the brain directly. Moreover, MCFAs, long-chain fatty acids, and glucose participate in mutually intertwined metabolic pathways. Therefore, the metabolic effects must be considered if the desired procognitive effects require administering MCT in doses larger than 1 g/kg. This review summarizes currently available research on the procognitive effects of using MCTs as a supplement to regular feed/diet without concomitant reduction of carbohydrate intake and focuses on the revealed mechanisms linked to particular MCT metabolites (ketone bodies, MCFAs), highlighting open questions and potential considerations.

1 October 2020 in Molecular and Cellular Probes
Verified
Journal Article
Closed access
ASAleksandr Schwarz
Aleksandr Schwarz
DMDaria A. Malygina
Daria A. Malygina
AKAnna A. Kovalenko
Anna A. Kovalenko
Alexander TrofimovAlexander Trofimov
Alexander Trofimov
AZAleksey V. Zaitsev
Aleksey V. Zaitsev

30 August 2017 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
TSTatyana Strekalova
Tatyana Strekalova
NBNataliia Bahzenova
Nataliia Bahzenova
Alexander TrofimovAlexander Trofimov
Alexander Trofimov
ASAngelika G. Schmitt-Böhrer
Angelika G. Schmitt-Böhrer
NMNataliia Markova
Nataliia Markova
Sergey BachurinSergey Bachurin
Sergey Bachurin

Verified
Journal Article
Open access
PDF file
TSTatyana Strekalova
Tatyana Strekalova
DPDmitrii A. Pavlov
Dmitrii A. Pavlov
Alexander TrofimovAlexander Trofimov
Alexander Trofimov
DADaniel C. Anthony
Daniel C. Anthony
ASAndrei Svistunov
Andrei Svistunov
RCRaymond Cespuglio
Raymond Cespuglio
The phenomenon of individual variability in susceptibility/resilience to stress and depression, in which the hippocampus plays a pivotal role, is attracting increasing attention. We investigated the potential role of hippocampal cyclooxygenase-2 (COX-2), which regulates plasticity, neuroimmune function, and stress responses that are all linked to this risk dichotomy. We used a four-week-long chronic mild stress (CMS) paradigm, in which mice could be stratified according to their susceptibility/resilience to anhedonia, a key feature of depression, to investigate hippocampal expression of COX-2, a marker of microglial activation Iba-1, and the proliferation marker Ki67. Rat exposure, social defeat, restraints, and tail suspension were used as stressors. We compared the effects of treatment with either the selective COX-2 inhibitor celecoxib (30 mg/kg/day) or citalopram (15 mg/kg/day). For the celecoxib and vehicle-treated mice, the Porsolt test was used. Anhedonic (susceptible) but not non-anhedonic (resilient) animals exhibited elevated COX-2 mRNA levels, increased numbers of COX-2 and Iba-1-positive cells in the dentate gyrus and the CA1 area, and decreased numbers of Ki67-positive cells in the subgranular zone of the hippocampus. Drug treatment decreased the percentage of anhedonic mice, normalized swimming activity, reduced behavioral despair, and improved conditioned fear memory. Hippocampal over-expression of COX-2 is associated with susceptibility to stress-induced anhedonia, and its pharmacological inhibition with celecoxib has antidepressant effects that are similar in size to those of citalopram.

6 December 2024 in Pathophysiology
Verified
Journal Article
Open access
PDF file
ASAlexey Sarapultsev
Alexey Sarapultsev
MKMaria V Komelkova
Maria V Komelkova
OLOleg Lookin
Oleg Lookin
SKSergey Khatsko
Sergey Khatsko
Evgenii Yurievich GusevEvgenii Yurievich Gusev
Evgenii Yurievich Gusev
DHDesheng Hu
Desheng Hu
Post-Traumatic Stress Disorder (PTSD) is a multifaceted psychiatric disorder triggered by traumatic events, leading to prolonged psychological distress and varied symptoms. Rat models have been extensively used to explore the biological, behavioral, and neurochemical underpinnings of PTSD. This review critically examines the strengths and limitations of commonly used rat models, such as single prolonged stress (SPS), stress–re-stress (S-R), and predator-based paradigms, in replicating human PTSD pathology. While these models provide valuable insights into neuroendocrine responses, genetic predispositions, and potential therapeutic targets, they face challenges in capturing the full complexity of PTSD, particularly in terms of ethological relevance and translational validity. We assess the degree to which these models mimic the neurobiological and behavioral aspects of human PTSD, highlighting areas where they succeed and where they fall short. This review also discusses future directions in refining these models to improve their utility for translational research, aiming to bridge the gap between preclinical findings and clinical applications.